Stem cell researchers: Better cytomegalovirus drugs are needed

09/22/2013 | Healio

Drug resistance was seen in almost 15% of hematopoietic stem cell transplant patients who received pre-emptive cytomegalovirus therapy in a study at Hadassah Hebrew University Medical Center in Israel. The study shows the need for cytomegalovirus drugs that act on different targets and can be better tolerated by patients, researchers wrote in The Journal of Infectious Diseases.

View Full Article in:

Healio

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC